Location History:
- Riom, FR (1987)
- Chatel-Guyon, FR (1984 - 1993)
Company Filing History:
3 out of 776 
2 out of 3 
1 out of 1 Years Active: 1984-1993
Title: Inventor Profile: Patrick Carlier
Introduction
Patrick Carlier, an innovative inventor based in Chatel-Guyon, France, has made significant contributions to the field of pharmaceutical chemistry. With a total of seven patents, his work primarily focuses on neuroleptic and antidepressant compounds, showcasing his expertise in developing new therapeutic agents.
Latest Patents
Carlier's latest patents include the invention of 4-[4- or 6-(trifluoromethyl-2-pyridinyl)]-1-piperazinylalkyl substituted lactam derivatives. These compounds are designed to enhance neuroleptic and antidepressant effects, boasting a general structure that demonstrates the incorporation of trifluoromethyl moieties. Another notable patent features pyridinylpiperazine derivatives, which exhibit improved preferential serotonin-1A binding activity. The unique formulas of these compounds indicate significant potential in addressing various psychiatric disorders.
Career Highlights
Throughout his career, Carlier has collaborated with prominent companies in the pharmaceutical industry, including Akzo N.V. and Riom Laboratories. His work in these organizations has advanced research in neuropharmacology and contributed to the development of effective psychiatric medications.
Collaborations
Carlier has worked alongside esteemed colleagues such as Andre J. Monteil and Jacques A. Simond, whose combined expertise has facilitated innovative advancements in their field. These collaborations have further enriched his research and invention portfolio, highlighting the collective effort in pharmaceutical innovation.
Conclusion
Patrick Carlier stands out as a dedicated inventor whose contributions have significantly impacted the pharmaceutical landscape. With his focus on neuroleptic and antidepressant compounds, his ongoing work promises to pave the way for new and effective treatments for mental health conditions. As he continues to explore new frontiers in pharmaceutical chemistry, the scientific community eagerly anticipates his future innovations.